SPRO 8-K 2026-07-14

Spero Therapeutics, Inc. (SPRO) 8-K dated 2026-07-14 — accession 0001193125-26-302473. This URL is the filing, not the SPRO hub.

Spero Therapeutics, Inc. (SPRO) is a biotechnology company listed on NASDAQ.

Spero Therapeutics, Inc. filed a 8-K on 2026-07-14. Accession 0001193125-26-302473.

Cached items: 1.01, 2.03, 7.01, 8.01, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported SPRO revenue for 2026-06-30 was $258.0K. Net income was -$16.8M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.

Not investment advice. The SPRO SEC hub lists recent forms. The stock page is the research view.